This aligns with a previous study demonstrating the activation of the IGF1/IGF1R pathway in mesenchymal gastric tumors, which displayed sensitivity to Linsitinib (OSI-906), another selective IGF-1R inhibitor (Oh et al., 2018). This evidence concerns the gene IGF1R and gastric neoplasm.